Special Issue on Treatment of Alzheimer’s Disease

Submission Deadline: Aug. 30, 2020

This special issue currently is open for paper submission and guest editor application.

Please download to know all details of the Special Issue

Special Issue Flyer (PDF)

  • Special Issue Editor
    • Zeynep Özdemir
      Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İnönü University, Malatya, Turkey
    Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
    • Mehtap Uysal
      Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erzincan Binali Yildirim University, Malatya, Turkey
    • Azime Berna Özçelik
      Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Malatya, Turkey
    • İnci Selin Doğan
      Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Karadeniz Technical University, Malatya, Turkey
    • Mehmet Abdullah Alagöz
      Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İnönü University, Malatya, Turkey
    • Arzu Karakurt
      Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İnönü University, Malatya, Turkey
  • Introduction

    Alzheimer's disease (AD) is a fatal neurodegenerative disease characterized by impaired ability to perform daily activities of the person and progressive cognitive dysfunctions and various neuropsychiatric symptoms in the later stages of the disease. The prevalence of AD, the most common form of dementia seen in the elderly, doubles every five years, reaching 1% at 60 years of age to 30% at 85 years of age (3). According to the results of the epidemiological studies on AD, it is estimated that the number of patients is approximately 5 million in the United States and 24 million in the world. Estimates are that this number will double in 20 years to reach 42 million in 2020 and 81 million in 2040. Although the physiopathology of AD is not yet fully understood, it is thought that the disease is caused by the indetected disappearance of brain cells and three main hypotheses (cholinergic hypothesis, amyloid hypothesis, Tau hypothesis) about the formation of the disease are suggested.
    Anticholinesterases are used in the treatment of diseases such as myasthenia gravis, atons in the gastrointestinal tract, glaucoma, Alzheimer. These compounds are also used as nerve gases and insecticides. Several cholinesterase inhibitors such as tacrine, donepezil, rivastigmine, galantamine and huperzine A have been shown to slow the progression of disease in AD.
    Aims and Scope:
    1. Cholinergic hypothesis
    2. Amiloid Hypothesis
    3. Tau Hypothesis
    4. Cholinesterase inhibitors
    5. Multitarget drugs for Alzheimer treatment
    6. MAO-B inhibitors on treatment of Alzheimer

  • Guidelines for Submission

    Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.

    Papers should be formatted according to the guidelines for authors (see: http://www.ijphmchem.org/submission). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.

  • Published Papers

    The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.

Browse journals by subject